P53 is activated in response to disruption of the pre-mRNA splicing machinery

Oncogene

Volumn 32, Issue 1, 2013, Pages 1-14

  Allende Vega, N ^a   Dayal, S ^a   Agarwala, U ^a   Sparks, A ^a   Bourdon, J C ^a   Saville, M K ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Mdm2; MdmX; p53; spliceosome; splicing; TG003

Indexed keywords

MESSENGER RNA; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RNA SPLICING; RNA TRANSCRIPTION; SPLICEOSOME; SPLICING DEFECT;

DNA DAMAGE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871985001     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.38     Document Type: Article

References (67)

1. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2: A001222.
2. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011; 8: 25-37.
3. Brooks CL, Gu W. p53 regulation by ubiquitin. FEBS Lett 2011; 585: 2803-2809.
4. Hock A, Vousden KH. Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 2010; 42: 1618-1621.
5. Lenos K, Jochemsen AG. Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011; 2011: 876173.
6. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
7. Marine JC, Dyer MA, Jochemsen AG. MDMX: From bench to bedside. J Cell Sci 2007; 120: 371-378.
8. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNAdamage kinases is required for p53 activation. EMBO J 2004; 23: 1547-1556.
9. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damageinduced MDMX degradation is mediated by MDM2. J Biol Chem 2003; 278: 45946-45953.
10. Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci USA 2007; 104: 12365-12370.
11. Will CL, Luhrmann R. Spliceosome Structure and Function. Cold Spring Harb Perspect Biol 2011; 3: 1-23.
12. Ritchie DB, Schellenberg MJ, MacMillan AM. Spliceosome structure: Piece by piece. Biochim Biophys Acta 2009; 1789: 624-633.
13. Newman AJ, Nagai K. Structural studies of the spliceosome: Blind men and an elephant. Curr Opin Struct Biol 2010; 20: 82-89.
14. Valadkhan S, Jaladat Y. The spliceosomal proteome: At the heart of the largest cellular ribonucleoprotein machine. Proteomics 2010; 10: 4128-4141.
15. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-1415.
16. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476.
17. Black DL. Protein diversity from alternative splicing: A challenge for bioinformatics and post-genome biology. Cell 2000; 103: 367-370.
18. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006; 126: 37-47.
19. Smith CW, Valcarcel J. Alternative pre-mRNA splicing: The logic of combinatorial control. Trends Biochem Sci 2000; 25: 381-388.
20. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
21. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010; 220: 152-163.
22. Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 2008; 1: 37-42.
23. Ritchie W, Granjeaud S, Puthier D, Gautheret D. Entropy measures quantify global splicing disorders in cancer. PLoS Comput Biol 2008; 4: E1000011.
24. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 2008; 10: R93.
25. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093.
26. Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C et al. Exonic expression profiling of breast cancer and benign lesions: A retrospective analysis. Lancet Oncol 2009; 10: 381-390.
27. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3: 570-575.
28. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3: 576-583.
29. Grainger RJ, Beggs JD. Prp8 protein: At the heart of the spliceosome. RNA 2005; 11: 533-557.
30. Wilkinson CR, Dittmar GA, Ohi MD, Uetz P, Jones N, Finley D. Ubiquitin-like protein Hub1 is required for pre-mRNA splicing and localization of an essential splicing factor in fission yeast. Curr Biol 2004; 14: 2283-2288.
31. Alexander R, Beggs JD. Cross-talk in transcription, splicing and chromatin: Who makes the first call? Biochem Soc Trans 2010; 38: 1251-1256.
32. Xiao SH, Manley JL. Phosphorylation of the ASF/SF2 RS domain affects both protein-protein and protein -RNA interactions and is necessary for splicing. Genes Dev 1997; 11: 334-344.
33. Cao W, Garcia-Blanco MA. A serine/arginine-rich domain in the human U1 70k protein is necessary and sufficient for ASF/SF2 binding. J Biol Chem 1998; 273: 20629-20635.
34. Hernandez H, Makarova OV, Makarov EM, Morgner N, Muto Y, Krummel DP et al. Isoforms of U1-70k control subunit dynamics in the human spliceosomal U1 snRNP. PLoS One 2009; 4: E7202.
35. Golas MM, Sander B, Will CL, Luhrmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science 2003; 300: 980-984.
36. Cass DM, Berglund JA. The SF3b155 N-terminal domain is a scaffold important for splicing. Biochemistry 2006; 45: 10092-10101.
37. Makarova OV, Makarov EM, Luhrmann R. The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J 2001; 20: 2553-2563.
38. Schaffert N, Hossbach M, Heintzmann R, Achsel T, Luhrmann R. RNAi knockdown of hPrp31 leads to an accumulation of U4/U6 di-snRNPs in Cajal bodies. EMBO J 2004; 23: 3000-3009.
39. Corrionero A, Minana B, Valcarcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 2011; 25: 445-459.
40. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004; 279: 24246-24254.
41. Ghosh G, Adams JA. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 2011; 278: 587-597.
42. Bartel F, Harris LC, Wurl P, Taubert H. MDM2 and its splice variant messenger RNAs: Expression in tumors and down-regulation using antisense oligonucleotides. Mol Cancer Res 2004; 2: 29-35.
43. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
44. Ljungman M. The transcription stress response. Cell Cycle 2007; 6: 2252-2257.
45. Svejstrup JQ. Contending with transcriptional arrest during RNAPII transcript elongation. Trends Biochem Sci 2007; 32: 165-171.
46. Brody Y, Neufeld N, Bieberstein N, Causse SZ, Bohnlein EM, Neugebauer KM et al. The in vivo kinetics of RNA polymerase II elongation during co-transcriptional splicing. PLoS Biol 2011; 9: E1000573.
47. Singh J, Padgett RA. Rates of in situ transcription and splicing in large human genes. Nat Struct Mol Biol 2009; 16: 1128-1133.
48. Kim MY, Hur J, Jeong S. Emerging roles of RNA and RNA-binding protein network in cancer cells. BMB Rep 2009; 42: 125-130.
49. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al. Cancerassociated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670-676.
50. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008; 24: 7-10.
51. Utans U, Behrens SE, Luhrmann R, Kole R, Kramer A. A splicing factor that is inactivated during in vivo heat shock is functionally equivalent to the [U4/U6.U5] triple snRNP-specific proteins. Genes Dev 1992; 6: 631-641.
52. Disher K, Skandalis A. Evidence of the modulation of mRNA splicing fidelity in humans by oxidative stress and p53. Genome 2007; 50: 946-953.
53. Zhao X, Yu YT. Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo. Nucleic Acids Res 2007; 35: 550-558.
54. Lain S, Midgley C, Sparks A, Lane EB, Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res 1999; 248: 457-472.
55. Sleeman J. A regulatory role for CRM1 in the multi-directional trafficking of splicing snRNPs in the mammalian nucleus. J Cell Sci 2007; 120: 1540-1550.
56. Busa R, Sette C. An emerging role for nuclear RNA-mediated responses to genotoxic stress. RNA Biol 2010; 7: 390-396.
57. Matsuoka S, Ballif BA, Smogorzewska A, McDonald 3rd ER, Hurov KE, Luo J et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-1166.
58. Katzenberger RJ, Marengo MS, Wassarman DA. ATM and ATR pathways signal alternative splicing of Drosophila TAF1 pre-mRNA in response to DNA damage. Mol Cell Biol 2006; 26: 9256-9267.
59. Munoz MJ, Perez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009; 137: 708-720.
60. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-2137.
61. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A et al. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett 2010; 584: 4463-4468.
62. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 2006; 66: 9502-9508.
63. Egecioglu DE, Chanfreau G. Proofreading and spellchecking: A two-tier strategy for pre-mRNA splicing quality control. RNA 2011; 17: 383-389.
64. Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 2009; 284: 5030-5041.
65. Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 2010; 29: 432-441.
66. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26: 976-986.
67. Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F et al. Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization. Cancer Res 2005; 65: 9687-9694.